

Appl. No. 10/787,018
Amdt. dated January 4, 2006
Reply to Office Action of October 5, 2005

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-36. (Canceled)

37. (Previously presented) A process for providing a pharmaceutical composition, comprising:

(a) identifying a modulator of the binding of CCX CKR polypeptide to a chemokine comprising

(i) contacting an isolated or recombinant CCX CKR polypeptide having the amino acid sequence as set forth in SEQ ID NO:2, or a fragment or variant thereof, and the chemokine in the presence of a test compound, and

(ii) comparing the level of binding of the chemokine and the polypeptide in the presence of the test compound with the level of binding in the absence of the test compound, wherein

the CCX CKR polypeptide, fragment or variant can bind the chemokine in the absence of test compound and the variant has at least 90% sequence identity to SEQ ID NO:2,

the chemokine is selected from the group consisting of ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1 γ (murine macrophage inflammatory protein 1 γ) and vMIPII (viral macrophage inflammatory protein II), and

Appl. No. 10/787,018
Amdt. dated January 4, 2006
Reply to Office Action of October 5, 2005

PATENT

a decrease in binding indicates that the test compound is an inhibitor of binding and an increase in binding indicates that the test compound is an enhancer of binding; and

(b) formulating the modulator identified in (a) as a pharmaceutical composition.

38. (Currently amended) The method of claim 37, wherein said contacting comprises contacting a cell expressing the CCX CKR polypeptide, fragment or variant.

39. (Previously presented) The method of claim 37, wherein the CCX CKR polypeptide, fragment or variant is part of a cell fraction.

40. (Previously presented) The method of claim 37, wherein the chemokine is ELC.

41. (Previously presented) The method of claim 37, wherein the chemokine is SLC.

42. (Previously presented) The method of claim 37, wherein the chemokine is TECK.

43. (Previously presented) The method of claim 37, wherein the chemokine is BLC.

44. (Previously presented) The method of claim 37, wherein the chemokine is CTACK.

45. (Previously presented) The method of claim 37, wherein the chemokine is mMIP-1 γ .

46. (Previously presented) The method of claim 37, wherein the chemokine is vMIPII.

Appl. No. 10/787,018
Amdt. dated January 4, 2006
Reply to Office Action of October 5, 2005

PATENT

47. (Previously presented) The method of claim 37, wherein the variant has at least 95% sequence identity to SEQ ID NO:2.

48. (Previously presented) The method of claim 47, wherein the variant has at least 98% sequence identity to SEQ ID NO:2.

49. (Previously presented) The method of claim 48, wherein the CCX CKR polypeptide has the amino acid sequence of SEQ ID NO:2.

50. (Previously presented) The method of claim 37, wherein formulating comprises combining the modulator with a pharmaceutically acceptable carrier.